Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies.

@article{Ilinykh2018EbolavirusCF,
  title={Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies.},
  author={Philipp A. Ilinykh and Jessica Graber and Natalia A. Kuzmina and Kai Huang and Thomas Ksiazek and James. E. Crowe and Alexander Bukreyev},
  journal={The Journal of infectious diseases},
  year={2018},
  volume={218 suppl\_5},
  pages={
          S418-S422
        }
}
Screening of monoclonal antibodies against ebolaviruses requires small-animal models. Wild-type mice require adaptation of ebolaviruses, whereas immunodeficient mice are still resistant to nonadapted Bundibugyo ebolavirus. Swapping of Ebola virus glycoprotein with that from Bundibugyo virus resulted in a replication-competent chimeric virus, which caused 100% lethal infection in STAT1 knockout mice. Monoclonal antibody BDBV223 isolated from a human survivor of Bundibugyo virus infection… 
View on PubMed
europepmc.org
6 Citations
Background Citations
1
Methods Citations
3

Figures from this paper

6 Citations

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

This approach facilitated investigation of the molecular and genetic basis for evolution of cross-reactive antibodies by elucidating germline-encoded properties of antibodies to EBOV and identification of the overlap between antibodies in the memory B-cell and serum repertoire.

Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV)

Signal transducer and activator of transcription-1 knock out mice were infected with five different wildtype filoviruses to determine susceptibility and favipiravir treatment fully protected STAT-1 KO mice from lethal SUDV challenge, suggesting that this may be an appropriate small animal model to screen anti-SUDV countermeasures.

A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.

The findings highlight the importance of specific effector functions in antibody-mediated protection, and the experimental platform presents a generalizable resource for identifying correlates of immunity to guide therapeutic antibody design.

Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses

Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.

References

SHOWING 1-10 OF 25 REFERENCES

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Mice serially passed EBO-Z virus in progressively older suckling mice, eventually obtaining a plaque-purified virus that was lethal for mature, immunocompetent BALB/c and C57BL/6 inbred and ICR (CD-1) outbred mice.

Filovirus infection of STAT-1 knockout mice.

A virus-like particle vaccine elicited strong antibody responses but did not protect against mouse-adapted ZEBOV challenge.

The role of the Type I interferon response in the resistance of mice to filovirus infection.

  • M. Bray
  • Biology, Medicine
    The Journal of general virology
  • 2001
Antibody treatment blocked the effect of a potent antiviral drug, 3-deazaneplanocin A, indicating that successful filovirus therapy may require the active participation of the Type I IFN response.

Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies

The study demonstrated that chimeric rhabdoviruses in which G protein is replaced with filovirus GP, widely used as surrogate targets for characterization of filov virus neutralizing antibodies, do not accurately predict the ability of antibodies to neutralize authentic filovirus, which appeared to be resistant to neutralization.

In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein.

It is demonstrated that the incorporation of a foreign gene will attenuate ZEBOV in vivo but that these viruses still have potential for in vitro and in vivo research applications.

Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses

The development of pan-ebolavirus and pan-filovirus antibodies generated by repeated immunization of mice with filovirus glycoproteins engineered to drive the B cell responses toward conserved epitopes are reported, including the first report of a cross-neutralizing antibody that exhibits protection against Ebola virus and Sudan virus in mice.

The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus

This work describes lethal models of disease for Bundibugyo, Sudan, and Zaire species of Ebolavirus in the domestic ferret, using wild-type nonadapted viruses.

The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence In Vivo

A novel reverse genetics system for REBOV is developed and direct evidence that GP contributes to filovirus virulence in vivo is provided, which clearly indicate that other factors are needed for the acquisition of full virulence.

Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.

It is determined that exposure to WT SUDV or EBOV results in reproducible signs of disease in IFNα/βR-/- mice, as measured by weight loss and partial lethality.

Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection